NCT00750256View on ClinicalTrials.gov

A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK1278863A in Healthy Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

36

Participants

Timeline

Start Date

July 7, 2008

Primary Completion Date

December 12, 2008

Study Completion Date

December 12, 2008

Conditions

Anaemia

Interventions

DRUG

GSK1278863A

GSK1278863A planned doses from 2mg to 450mg which may change based on safety or PK from previous cohorts.

Trial Locations (1)

47710

GSK Investigational Site, Evansville

Sponsors

Lead Sponsor

GlaxoSmithKline

All Listed Sponsors

lead

GlaxoSmithKline

INDUSTRY

NCT00750256 - A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK1278863A in Healthy Subjects | Biotech Hunter | Biotech Hunter